Format

Send to

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 2012 Dec;67(6):1265-72. doi: 10.1016/j.jaad.2012.04.008. Epub 2012 May 18.

Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Author information

1
Department of Dermatology, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. emily.chu@uphs.upenn.edu

Abstract

BACKGROUND:

Vemurafenib, a novel selective small molecule inhibitor of BRAF, has recently been shown to be effective in the treatment of melanomas harboring the BRAF V600E mutation. Similar to the broad-spectrum RAF inhibitor sorafenib, vemurafenib induces development of squamous cell carcinomas and keratoacanthomas as a side effect of therapy.

OBJECTIVE:

We sought to detail additional cutaneous adverse effects of vemurafenib and a similar BRAF inhibitor, dabrafenib.

METHODS:

We evaluated the clinical and histologic feature of skin side effects developing on vemurafenib or dabrafenib therapy in 14 patients.

RESULTS:

Eight patients developed one or more squamous cell carcinomas, and 11 patients formed benign verrucous keratoses. Eight patients developed single lesions and/or widespread eruptions with histopathologic findings of acantholytic dyskeratosis, consistent with warty dyskeratomas and Darier- or Grover-like rashes, respectively. One patient developed palmoplantar hyperkeratosis, and darkening of existing nevi and new nevi within 2 months of starting vemurafenib. Side effects presented as early as 1 week after beginning therapy, with a mean time of onset of 12.6 weeks in our cohort.

LIMITATIONS:

This study was limited by the small number of cases, all from a single institution.

CONCLUSION:

Selective BRAF inhibitor therapy is associated with the development of malignant and benign growths, including keratoacanthoma-like squamous cell carcinomas, warty dyskeratomas, and verrucous keratoses, along with widespread eruptions with histologic features of acantholytic dyskeratosis. Given the potential for malignant lesions to develop on treatment, awareness of potential adverse effects of these agents is necessary, and a low threshold for biopsy of new growths is recommended.

PMID:
22609219
PMCID:
PMC4838029
DOI:
10.1016/j.jaad.2012.04.008
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center